You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 11, 2025

CLINICAL TRIALS PROFILE FOR ZINC CHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Zinc Chloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT00016744 ↗ Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous(for Cystic Fibrosis) Completed Cystic Fibrosis Foundation Phase 1/Phase 2 2001-09-01 We are testing a new combination of medicines, to determine if they could be used to treat cystic fibrosis (CF). Subjects with CF who have two copies of the most common mutation (change) found in patients with CF called DF508. CF is caused by a lack of chloride movement in the nose, sinuses, lungs, intestines, pancreas and sweat glands. We are conducting this study to determine the safety of using a combination of two medicines, Phenylbutyrate and Genistein, to improve the ability of the cells lining the nose to regulate movement of salt (chloride) and water in people with CF. Phenylbutyrate has been extensively used to treat patients with rare metabolic diseases (which are very different from CF), Phenylbutyrate is an investigational drug for the purpose of this study. Genistein is a naturally occurring substance that is found in food products such as soy and tofu, but is also an investigational drug for this study. Both drugs may be able to restore normal chloride movements in body organs and glands. We will be studying salt and water in the nose movement by a technique called nasal transepithelial potential difference (NPD).
New Combination NCT00016744 ↗ Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous(for Cystic Fibrosis) Completed Cystic Fibrosis Foundation Therapeutics Phase 1/Phase 2 2001-09-01 We are testing a new combination of medicines, to determine if they could be used to treat cystic fibrosis (CF). Subjects with CF who have two copies of the most common mutation (change) found in patients with CF called DF508. CF is caused by a lack of chloride movement in the nose, sinuses, lungs, intestines, pancreas and sweat glands. We are conducting this study to determine the safety of using a combination of two medicines, Phenylbutyrate and Genistein, to improve the ability of the cells lining the nose to regulate movement of salt (chloride) and water in people with CF. Phenylbutyrate has been extensively used to treat patients with rare metabolic diseases (which are very different from CF), Phenylbutyrate is an investigational drug for the purpose of this study. Genistein is a naturally occurring substance that is found in food products such as soy and tofu, but is also an investigational drug for this study. Both drugs may be able to restore normal chloride movements in body organs and glands. We will be studying salt and water in the nose movement by a technique called nasal transepithelial potential difference (NPD).
New Combination NCT00016744 ↗ Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous(for Cystic Fibrosis) Completed National Center for Research Resources (NCRR) Phase 1/Phase 2 2001-09-01 We are testing a new combination of medicines, to determine if they could be used to treat cystic fibrosis (CF). Subjects with CF who have two copies of the most common mutation (change) found in patients with CF called DF508. CF is caused by a lack of chloride movement in the nose, sinuses, lungs, intestines, pancreas and sweat glands. We are conducting this study to determine the safety of using a combination of two medicines, Phenylbutyrate and Genistein, to improve the ability of the cells lining the nose to regulate movement of salt (chloride) and water in people with CF. Phenylbutyrate has been extensively used to treat patients with rare metabolic diseases (which are very different from CF), Phenylbutyrate is an investigational drug for the purpose of this study. Genistein is a naturally occurring substance that is found in food products such as soy and tofu, but is also an investigational drug for this study. Both drugs may be able to restore normal chloride movements in body organs and glands. We will be studying salt and water in the nose movement by a technique called nasal transepithelial potential difference (NPD).
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Zinc Chloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000522 ↗ Treatment of Mild Hypertension Study (TOMHS) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 2 1985-08-01 To compare the effects of nonpharmacologic therapy alone with those of one of five active drug regimens combined with non-pharmacologic therapy, for long- term management of patients with mild hypertension.
NCT00000522 ↗ Treatment of Mild Hypertension Study (TOMHS) Completed University of Minnesota Phase 2 1985-08-01 To compare the effects of nonpharmacologic therapy alone with those of one of five active drug regimens combined with non-pharmacologic therapy, for long- term management of patients with mild hypertension.
NCT00000522 ↗ Treatment of Mild Hypertension Study (TOMHS) Completed University of Minnesota - Clinical and Translational Science Institute Phase 2 1985-08-01 To compare the effects of nonpharmacologic therapy alone with those of one of five active drug regimens combined with non-pharmacologic therapy, for long- term management of patients with mild hypertension.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zinc Chloride

Condition Name

Condition Name for Zinc Chloride
Intervention Trials
Cystic Fibrosis 49
Healthy 27
Pain 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zinc Chloride
Intervention Trials
Fibrosis 52
Cystic Fibrosis 50
Kidney Diseases 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zinc Chloride

Trials by Country

Trials by Country for Zinc Chloride
Location Trials
United States 810
China 71
Australia 49
Germany 49
Canada 41
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zinc Chloride
Location Trials
California 64
Texas 57
Illinois 36
Florida 35
North Carolina 35
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zinc Chloride

Clinical Trial Phase

Clinical Trial Phase for Zinc Chloride
Clinical Trial Phase Trials
Phase 4 195
Phase 3 134
Phase 2/Phase 3 28
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zinc Chloride
Clinical Trial Phase Trials
Completed 422
Recruiting 125
Unknown status 67
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zinc Chloride

Sponsor Name

Sponsor Name for Zinc Chloride
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 13
Cystic Fibrosis Foundation 12
Vertex Pharmaceuticals Incorporated 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zinc Chloride
Sponsor Trials
Other 977
Industry 299
NIH 46
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Zinc Chloride: Clinical Trials, Market Analysis, and Projections

Clinical Trials and Efficacy of Zinc Chloride

Zinc Chloride in COVID-19 Treatment

Recent clinical trials have explored the efficacy of zinc supplementation, including zinc chloride, in the treatment of COVID-19. A prospective, randomized, double-blind, placebo-controlled multicenter trial investigated the effects of oral zinc on COVID-19 patients. The study found that oral zinc supplementation reduced the 30-day mortality rate, ICU admission rate, and shortened the duration of COVID-19 symptoms. Specifically, the zinc group had a 6.5% mortality rate and a 5.2% ICU admission rate, compared to 9.2% and 11.3%, respectively, in the placebo group. The combined outcome of death or ICU admission was significantly lower in the zinc group[1].

Zinc Chloride in Oral Mucositis Treatment

Another clinical trial evaluated the effectiveness of zinc chloride mouthwash in treating oral mucositis in cancer patients. The study revealed that zinc chloride mouthwash, along with sodium bicarbonate mouthwash, significantly reduced the severity of oral mucositis and improved the quality of life for patients. The severity of mucositis decreased from the first week to the third week in both the zinc chloride and sodium bicarbonate groups compared to the placebo group[4].

Market Analysis of Zinc Chloride

Current Market Size and Growth

The global zinc chloride market is experiencing substantial growth driven by increasing demand from various sectors. As of 2023, the market size is estimated to be around $309.6 million and is projected to reach $505.6 million by 2033, growing at a Compound Annual Growth Rate (CAGR) of 5.0% during this period[2][5].

Key Sectors Driving Demand

Several sectors are driving the demand for zinc chloride:

  • Chemicals and Pharmaceuticals: Zinc chloride is used as a catalyst, flux, and desiccant in various chemical reactions and manufacturing processes. Its role in the production of medicines, antiseptics, and wound care treatments is significant[2][5].
  • Agriculture: Zinc chloride is an essential micronutrient in fertilizers, contributing to its demand in agricultural sectors[5].
  • Electronics: The increasing use of zinc chloride in the production of batteries, especially zinc-carbon batteries, is a key driver in the electronics sector[5].
  • Cosmetics and Personal Care: The antibacterial qualities of zinc chloride make it a valuable component in oral hygiene products, antiseptics, and other personal care items[2][3].

Regional Market Dynamics

  • Asia Pacific: This region has emerged as the largest market for zinc chloride, driven by countries like India and China. India’s zinc chloride industry is expected to create an absolute dollar opportunity of over $25 million, while China’s industry is anticipated to create an opportunity of over $40 million by the end of the forecast period[2][5].
  • India and China: These countries are significant consumers and producers of zinc chloride, with growing demands from their chemical, pharmaceutical, and agricultural sectors[2][5].

Market Projections

Future Growth and Opportunities

The global zinc chloride market is poised for substantial growth, driven by several factors:

  • CAGR and Market Size: The market is expected to grow at a CAGR of 5.0% from 2023 to 2033, reaching a market size of $505.6 million by 2033[2][5].
  • High Purity Segment: The high purity segment of zinc chloride is anticipated to dominate the market, expanding at a CAGR of 4.9% and creating a growth opportunity of about $100 million during the forecast period[5].
  • Sustainable Energy: The increasing focus on sustainable energy sources and environmental regulations is driving the demand for zinc chloride in the production of solar cells and other energy storage devices[5].

Challenges and Opportunities

  • Expanding Applications: The diverse applications of zinc chloride, including its use in textiles, rubber, plastics, and renewable energy technologies, present significant growth opportunities[5].
  • Government Initiatives: Favorable government initiatives to promote green energy and sustainable practices are expected to further boost the demand for zinc chloride[3].

Key Takeaways

  • Clinical Efficacy: Zinc chloride has shown promising results in clinical trials for treating COVID-19 and oral mucositis.
  • Market Growth: The global zinc chloride market is projected to grow at a CAGR of 5.0% from 2023 to 2033.
  • Sectoral Demand: Demand is driven by the chemicals, pharmaceuticals, agriculture, electronics, and cosmetics sectors.
  • Regional Dynamics: Asia Pacific, particularly India and China, are key regions driving market growth.
  • Future Opportunities: High purity zinc chloride and its role in sustainable energy technologies are expected to be significant growth drivers.

FAQs

What are the primary sectors driving the demand for zinc chloride?

The primary sectors driving the demand for zinc chloride include chemicals, pharmaceuticals, agriculture, electronics, and cosmetics.

How effective is zinc chloride in treating COVID-19?

Clinical trials have shown that oral zinc supplementation, including zinc chloride, can reduce 30-day mortality rates, ICU admission rates, and shorten the duration of COVID-19 symptoms.

What is the projected market size of the global zinc chloride market by 2033?

The global zinc chloride market is projected to reach $505.6 million by 2033.

Which region is the largest market for zinc chloride?

The Asia Pacific region, particularly India and China, is the largest market for zinc chloride.

What are the key applications of zinc chloride in the electronics sector?

Zinc chloride is used in the production of batteries, especially zinc-carbon batteries, which are widely used in consumer electronics such as remote controls, flashlights, and toys.

Sources

  1. Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus ... - Academic.oup.com
  2. Global Zinc Chloride Market Poised for Substantial Growth - Globenewswire.com
  3. Zinc Chloride Market Size & Industry Analysis - Thebrainyinsights.com
  4. Effectiveness of sodium bicarbonate and zinc chloride mouthwashes ... - Onlinelibrary.wiley.com
  5. Zinc Chloride Market Share, Trends & Forecast of 2033 - Futuremarketinsights.com

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.